TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00262106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PRO 2000/5
Description: Gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT02809248

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ZES
Description: stent implantation (zotarolimus eluting stent)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BMS
Description: stent implantation (bare metal stent)
Study: NCT02801357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lofexidine administration in subjects seeking buprenorphine dose reduction
Study: NCT00005037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide capsule once a day for 42 days every 10 weeks.
Study: NCT03037294

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative protein supplementation
Description: Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
Study: NCT04284644

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction using propofol
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, a dose of 1.5 mg/kg of propofol slowly over 2 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction using sevoflurane
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 8% inhalational sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Induction using propofol and sevoflurane
Description: Patients were given 1.5 mcg/Kg of fentanyl intravenously. two minutes after the fentanyl dose, patient received 4% sevoflurane through sealed plastic face mask at 8 L/min flow of oxygen for 2 minutes, followed by a dose of 0.75 mg/kg of propofol given slowly.
Study: NCT04063761

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: esophageal cooling device (Attune Medical, Chicago, IL)
Description: Prospective, single center pilot study
Study: NCT00957372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: oral tablet, 800 mg or 1200 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eslicarbazepine acetate
Description: oral tablet, 800 mg or 1200 mg once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (Part I)
Description: once daily placebo comparator
Study: NCT05172180

Intervention type: DRUG
Intervention: Ringer's solution
Description: Ringer's solution at an average daily dose of 8.1 ml/kg/day
Study: NCT02487355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Magnesium Sulphate 50 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 1ml/kg of 0.25%of bupivacaine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine + Magnesium Sulphate + Bupivacaine
Description: Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
Study: NCT03565653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High dietary salt
Description: \~4,000 mg Na+/day
Study: NCT02624414

Intervention type: DEVICE
Group type: OTHER
Intervention: PillCam® COLON 2 Capsule Endoscopy
Study: NCT02867592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO~Note: Capsule formulation (Cometriq) not used in this trial.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03520647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cells
Description: This research protocol is therefore designed to evaluate the safety and effectiveness of using an unmanipulated G-CSF mobilized peripheral stem cell allograft from a haploidentical donor and post-transplant cyclophosphamide for patients with SAA, or SAA evolving to MDS, or PNH that has proven to be refractory to conventional immunosuppressive therapy (IST) in patients who lack an HLA-matched donor (sibling/ or matched unrelated donor.
Study: NCT00957372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESL - Open-label Extension (Part II)
Description: Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
Study: NCT03565653

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: dextrose
Study: NCT03519945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirikizumab
Description: Administered SC.
Study: NCT04345874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Children's environmental health technical assistance
Description: Participating family child care home providers in rural counties will be randomized to either the Nutrition Intervention (n=27), or an environmental health comparison group (n=27) that will receive an Integrated Pest Management and Green Cleaning intervention with the same format and visit frequency. Briefly, the Nutrition Technical Assistance Intervention and comparison group will consist of three encounters with our intervention team: two 60-90 minutes virtual one-on-one visits scheduled at the convenience of the family child care home provider and a 3-hour virtual group class session with other providers. Total contact time with intervention staff will be 6 hours. All participants will receive a toolkit. Providers will complete either intervention virtually over a period of three months.
Study: NCT01899703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2330672
Description: GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
Study: NCT04632849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GEM + CGM
Description: Participants follow the GEM guidebook for 4 months (1 month of intervention and 3 months of maintenance) while wearing a FitBit activity monitor and a Freestyle Libre 2 CGM to provide feedback about activity and blood glucose. The GEM guidebook covers Routine choices, Recovering from blood glucose excursions, Reducing blood glucose excursions, and Maintenance.
Study: NCT01441544

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variety of Active Videogames
Description: Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Variety of Active Videogames
Description: Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
Study: NCT00584350

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydratation according LVEDP + NaHCO3
Description: Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.~At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
Study: NCT03980093

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education
Description: Online medical education on the benefits of anti-hormonal medication, potential side effects, and how to manage them.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values
Description: An Acceptance and Commitment Therapy (ACT)-based intervention consisting of brief online sessions plus a visual cue-based intervention focused on personal values.
Study: NCT00969722

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAb-3F8

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 13-cis-Retinoic Acid
Study: NCT05518786

Intervention type: OTHER
Intervention: Exposure of interest: critical illness
Description: Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae

Intervention type: OTHER
Intervention: Exposure of interest: critical illness
Description: Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae

Intervention type: OTHER
Intervention: Exposure of interest: critical illness
Description: Patients admitted to an intensive care unit (ICU) will be followed-up to evaluate post-ICU long-term sequelae
Study: NCT00793923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ranibizumab and dexamethasone
Description: Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab
Description: intravitreal injection of 0.5 mg ranibizumab
Study: NCT04595955

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CMyLife
Description: CMyLife is a digital patient platform for Patients With Chronic Myeloid Leukemia.
Study: NCT00907738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
Study: NCT03707093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADG106
Description: IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg,10 mg/kg or 300mg flat dose depending on cohort at enrollment.
Study: NCT03020511

Intervention type: OTHER
Group type: OTHER
Intervention: Ancient wheat flours
Description: Ancient wheat flours will be administered in open label for 30 days
Study: NCT03580057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Description: Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breastfeeding promotion intervention
Description: Promotion (education, support and supervision) of breastfeeding by experienced breastfeeding consultants and midwife, in order to follow the Norwegian guideline of 6 months exclusive breastfeeding and partial breastfeeding for a year.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and weight loss intervention
Description: 12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
Study: NCT00140465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: after PCI
Study: NCT01899703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid
Description: UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
Study: NCT03971513

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trans abdominal plane
Description: Trans abdominal plane block is performed with ultra sound guidance.~1. - The high frequency probe is placed right to the umbilicus, and slips laterally to the side to block. It allows showing the three belts of larges muscles of abdomen (External Oblicum, internal oblicum, and transversal of the abdomen).~2. - When the needle is visualised in the plan separating the muscle internal oblicum and transversal of the abdomen, 20 ml of ropivacaïne 5mg/ml are injected after aspiration test. If in doubt, hydro localisation car be realised.
Study: NCT00505492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5 by vein once every 28 Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40 mg/m\^2 by vein (IV) Weekly Over 4 Hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 135 mg/m\^2 by vein (IV) Once Every 28 Days
Study: NCT03580057

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and weight loss intervention
Description: 12-week program of dietary behavior modification treatment (LEVA-method by Bertz et al. Am J Clin Nutr 2012;96:698), leading to 6 kg weight loss (0.5 kg per week) and a healthier diet (less sugar, snacks, full fat products, more vegetables and fruit, smaller portion sizes). Weight is monitored by phone contact every second week. After 12 weeks, the women are followed up by e-mail contact for 9 additional months.
Study: NCT02040064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: IV
Study: NCT04688944

Intervention type: OTHER
Intervention: observation
Description: observation the difference between two groups
Study: NCT06742216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Monosialoganglioside
Description: Monosialoganglioside diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo diluted with 0.9% normal saline 100ml, iv, daily for 12-14 days
Study: NCT04236596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Participants received a Neurostimulator, which was used to map the pudendal nerve
Description: Participants in study received neurostimulator at their pudendal nerve as part of their normal clinical care. This neurostimulator was used to map the nerve.
Study: NCT00471107

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: DC brain polarization
Description: 0.08 mA/cm2
Study: NCT00334750

Intervention type: OTHER
Intervention: There is no intervention in this study.
Description: This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
Study: NCT02941731

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1403
Description: Oseltamivir 6mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1403
Description: Oseltamivir 6mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0919
Description: Oseltamivir phosphate 6mg/mL

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0919
Description: Oseltamivir phosphate 6mg/mL
Study: NCT03375710

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cordella™ Heart Failure System
Description: The Cordella™ Heart Failure System collects, records, and transmits physiologic data and communications from the patient at home to clinicians for assessment, patient communication, and patient-centered heart failure management. The system consists of the following components:~1. myCordella™ Patient Management Portal~2. myCordella™ Hub~3. myCordella™ Peripherals, including the Cordella™ Pulmonary Artery Sensor System (CorPASS)
Study: NCT02132390

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toremifene
Study: NCT03842709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole Oral Tablet
Description: Initial dosage of 0.125 mg pramipexole daily, potentially titrated upward in 0.125 increments to a maximum of 0.5 mg daily, for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administration of placebo
Study: NCT01777633

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Palliative re-irradiation for progressive DIPG in children
Study: NCT03873597

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-coaching + Usual Care
Description: The tele-coaching intervention will be delivered for 3 months following discharge from hospital. This consists of: 1) An interview discussing motivational issues, favourite daily activities and strategies to become more physically active; 2) a step counter 3) a smart phone with tele-coaching application providing activity goals (daily steps), feedback and educational tips on a daily basis. Patients' targets will be automatically revised on a weekly basis, based on performance in the preceding week; (4) a booklet containing home exercises; (5) weekly activity proposals; (6) tele-phone contacts triggered in the case of non-compliance, failure to transmit data or difficulty to progress.
Study: NCT02734563

Intervention type: OTHER
Intervention: Collagen turnover
Description: Type IV and V collagen synthesis and breakdown

Intervention type: OTHER
Intervention: Collagen turnover
Description: Type IV and V collagen synthesis and breakdown
Study: NCT04295902

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C-MAC indirect videolaryngoscope with blades Miller nr 0 and Miller nr 1.
Description: Tracheal intubation performed with the C-MAC indirect videolaryngoscope (Karl Storz, Tuttlingen, Germany) with blades Miller nr 0 and Miller nr 1.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct laryngoscope with blades Miller nr 0 and Miller nr 1.
Description: Tracheal intubation performed with a standard direct laryngoscope, with standard blades Miller nr 0 and Miller nr 1
Study: NCT02978014

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProSpare
Description: A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
Study: NCT00671151

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Theophylline
Description: Theophylline 100 mg bid for 3 months
Study: NCT00704106

Intervention type: DRUG
Intervention: Entecavir
Description: 0.5 or 1 mg dose qd

Intervention type: DRUG
Intervention: Entecavir
Description: 0.5 or 1 mg dose qd

Intervention type: DRUG
Intervention: Entecavir
Description: 0.5 or 1 mg dose qd

Intervention type: DRUG
Intervention: Entecavir
Description: 0.5 or 1 mg dose qd
Study: NCT00893711

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938
Description: Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: L.reuteri + Vit D

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Vit D placebo
Study: NCT02286960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Steroid
Description: A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Pills
Description: 4 day course 2 x 20mg per da